A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma N. Tan (S, Singapore), M. Mukherjee (Toronto, Canada), S. Lim (Singapore, Singapore), C. Thiam (Singapore, Singapore), W. Tan (Singapore, Singapore), W. Wong (Singapore, Singapore), P. Nair (Toronto, Canada), V. Angeli (Singapore, Singapore), H. Lim (Singapore, Singapore)
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Disease area: Airway diseasesRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Tan (S, Singapore), M. Mukherjee (Toronto, Canada), S. Lim (Singapore, Singapore), C. Thiam (Singapore, Singapore), W. Tan (Singapore, Singapore), W. Wong (Singapore, Singapore), P. Nair (Toronto, Canada), V. Angeli (Singapore, Singapore), H. Lim (Singapore, Singapore). A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma. 2530
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A retrospective observational study to characterize severe eosinophilic asthma in Taiwan Source: International Congress 2018 – Asthma and allergy in adults and children and their biomarkers Year: 2018
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020 Year: 2020
A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis Source: Eur Respir J , 49 (3) 1602486; DOI: 10.1183/13993003.02486-2016 Year: 2017
A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019
Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Cross-sectional, observational study to estimate the prevalence of the eosinophilic phenotype for Brazilian patients with severe asthma: the BRAEOS study Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020
Metabolomic approach in the characterization of omalizumab responders and non-responders among children with severe asthma: a multicenter prospective study. Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021
The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
The patterns of inadequate drug administration in children with asthma: a multi-center retrospective study Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002
Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012
Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study Source: ERJ Open Res, 6 (1) 00172-2019; 10.1183/23120541.00172-2019 Year: 2020
Development of asthma in patients with eosinophilic bronchitis: prospective follow up study Source: Eur Respir J 2002; 20: Suppl. 38, 51s Year: 2002
Short-term HRQL deterioration during early-phase COPD exacerbation: a prospective Canadian cohort study Source: Eur Respir J 2005; 26: Suppl. 49, 296s Year: 2005
Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study Source: ERJ Open Res, 5 (1) 00175-2018; 10.1183/23120541.00175-2018 Year: 2019